GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » Total Inventories

MaxCyte (MaxCyte) Total Inventories : $11.96 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is MaxCyte Total Inventories?

MaxCyte's total inventories for the quarter that ended in Mar. 2024 was $11.96 Mil. MaxCyte's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $12.09 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. MaxCyte's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.31.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. MaxCyte's Days Inventory for the three months ended in Mar. 2024 was 786.62.

Inventory Turnover measures how fast the company turns over its inventory within a year. MaxCyte's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.12.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. MaxCyte's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.07.


MaxCyte Total Inventories Historical Data

The historical data trend for MaxCyte's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Total Inventories Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.70 4.32 5.21 8.58 12.23

MaxCyte Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.27 11.02 12.53 12.23 11.96

MaxCyte Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


MaxCyte  (NAS:MXCT) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

MaxCyte's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(157.513+0.75 * 5.991+0.5 * 11.96-31.571
-0-0)/104.405
=1.31

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

MaxCyte's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=12.0945/1.403*365 / 4
=786.62

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

MaxCyte's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=1.403 / 12.0945
=0.12

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

MaxCyte's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=12.0945 / 11.342
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


MaxCyte Total Inventories Related Terms

Thank you for viewing the detailed overview of MaxCyte's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


MaxCyte (MaxCyte) Business Description

Traded in Other Exchanges
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Executives
John Joseph Johnston director C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler director, officer: President and CEO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Thomas M. Ross officer: EVP, Global Sales C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Douglas J Swirsky officer: Chief Financial Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Patrick J Balthrop director C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen officer: Chief Scientific Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy officer: Chief Financial Officer C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud officer: EVP and General Counsel C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz officer: SVP and CAO C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell director C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke director 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Thompson J Stark Phd director